Eli Lilly and Company has taken the lead in in the development and tirzepatide, a groundbreaking medication for type 2 diabetes. Tirzepatide, a dual GIP and GLP-1 receptor agonist, showcases significant capacity to improve glycemic control and reduce heart disease. The sophisticated synthesis of tirzepatide requires a series of meticulous processes